In search of novel ligands using a structure-based approach: a case study on the adenosine A2A receptor

In this work, we present a case study to explore the challenges associated with finding novel molecules for a receptor that has been studied in depth and has a wealth of chemical information available. Specifically, we apply a previously described protocol that incorporates explicit water molecules in the ligand binding site to prospectively screen over 2.5 million drug-like and lead-like compounds from the commercially available eMolecules database in search of novel binders to the adenosine A2A receptor (A2AAR). A total of seventy-one compounds were selected for purchase and biochemical assaying based on high ligand efficiency and high novelty (Tanimoto coefficient ≤0.25 to any A2AAR tested compound). These molecules were then tested for their affinity to the adenosine A2A receptor in a radioligand binding assay. We identified two hits that fulfilled the criterion of ~50 % radioligand displacement at a concentration of 10 μM. Next we selected an additional eight novel molecules that were predicted to make a bidentate interaction with Asn2536.55, a key interacting residue in the binding pocket of the A2AAR. None of these eight molecules were found to be active. Based on these results we discuss the advantages of structure-based methods and the challenges associated with finding chemically novel molecules for well-explored targets.

[1]  Woody Sherman,et al.  Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods , 2010, J. Cheminformatics.

[2]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[3]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[4]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[5]  Woody Sherman,et al.  Computational approaches for fragment-based and de novo design. , 2010, Current topics in medicinal chemistry.

[6]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[7]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[8]  Nathan Robertson,et al.  Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.

[9]  Jean-Louis Reymond,et al.  Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17 , 2012, J. Chem. Inf. Model..

[10]  Manjit,et al.  Neurology , 1912, NeuroImage.

[11]  Jonathan S. Mason,et al.  Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.

[12]  Ronald J. Quinn,et al.  High-Pressure Synthesis of Enantiomerically Pure C-6 Substituted Pyrazolo[3,4-d]pyrimidines , 2001 .

[13]  Hugo Gutiérrez-de-Terán,et al.  Sodium Ion Binding Pocket Mutations and Adenosine A2A Receptor Function , 2015, Molecular Pharmacology.

[14]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[15]  Stefano Manfredini,et al.  Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists. , 1994 .

[16]  Jonathan W. Essex,et al.  Water Network Perturbation in Ligand Binding: Adenosine A2A Antagonists as a Case Study , 2013, J. Chem. Inf. Model..

[17]  David Rodríguez,et al.  Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor , 2015, J. Chem. Inf. Model..

[18]  A. IJzerman,et al.  Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. , 2001, Journal of medicinal chemistry.

[19]  Tzvetelina Dimitrova,et al.  Adenosine A2A receptor antagonist treatment of Parkinson’s disease , 2003, Neurology.

[20]  Thorsten Meinl,et al.  KNIME: The Konstanz Information Miner , 2007, GfKl.

[21]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[22]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[23]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[24]  Andreas Bender,et al.  Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..

[25]  Adriaan P. IJzerman,et al.  Complementarity between in Silico and Biophysical Screening Approaches in Fragment-Based Lead Discovery against the A2A Adenosine Receptor , 2013, J. Chem. Inf. Model..

[26]  L. Christophorou Science , 2018, Emerging Dynamics: Science, Energy, Society and Values.

[27]  Sergi Ferré,et al.  Antagonistic A2a/D2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system , 1993 .

[28]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[29]  Woody Sherman,et al.  Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments , 2010, J. Chem. Inf. Model..

[30]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[31]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[32]  Andreas Bender,et al.  A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. , 2012, Journal of medicinal chemistry.

[33]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[34]  Nitin Kumar,et al.  Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists. , 2013, Bioorganic & medicinal chemistry.

[35]  P. Jenner,et al.  A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD , 2003, Neurology.

[36]  Woody Sherman,et al.  Boosting Virtual Screening Enrichments with Data Fusion: Coalescing Hits from Two-Dimensional Fingerprints, Shape, and Docking , 2013, J. Chem. Inf. Model..

[37]  Richard A. Friesner,et al.  Integrated Modeling Program, Applied Chemical Theory (IMPACT) , 2005, J. Comput. Chem..

[38]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[39]  J. Irwin,et al.  Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.

[40]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[41]  R. Friesner,et al.  The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling , 2011, Proteins.

[42]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[43]  C. Martini,et al.  1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.

[44]  J. Reymond The chemical space project. , 2015, Accounts of chemical research.

[45]  E. Novellino,et al.  2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. , 2005, Journal of medicinal chemistry.

[46]  Woody Sherman,et al.  Selecting an Optimal Number of Binding Site Waters To Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor , 2014, J. Chem. Inf. Model..

[47]  Jens Carlsson,et al.  Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. , 2012, ACS medicinal chemistry letters.